The development of MORAb-004, initially identified as MORAb-004, represents a important effort in cancer treatment. Scientists at the company began research on a modified monoclonal protein targeting CD3, focused the purpose of engaging immune cells to kill malignant cells. Initial clinical trials indicated potential in blood malignancies, parti… Read More